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hAdvanced and Relapsed/Refractory
Hodgkin Lymphoma: What Has Been
Achieved During the Last 50 Years
Theodoros P. Vassilakopoulos and Maria K. Angelopoulou
During the last 50 years there has been great progress in understanding the biology of Hodgkin
disease, which is now called Hodgkin lymphoma (HL), since it has been definitely shown to be a
lymphoid neoplasm and its B-cell origin has been documented in the vast majority of cases. Progress
in biology has also resulted in the identification of numerous biological prognostic factors, which
may facilitate the definition of high-risk groups of patients and provide guidance for individualized
therapy. Unfortunately, biological prognostic factors have not been incorporated in prognostic
models applicable in everyday practice and need prospective validation. More importantly, during
the last 50 years, advanced stage HL has been transformed from a rather incurable into a highly
curable disease. Chemotherapy has gradually improved in terms of efficacy. MOPP was replaced by
the more efficacious and less toxic ABVD regimen, but higher cure rates with BEACOPP-escalated
have come at the expense of increased toxicity. Better risk stratification, probably based on early,
interim positron emission tomography (PET) evaluation, may in the near future better identify those
patients who really need intensified chemotherapy. Furthermore, the intensification of chemother-
apy and the optimal use of PET at the end of chemotherapy have already minimized the use of
radiotherapy in advanced disease, thus reducing the risk of long-term complications. Relapsed and
refractory disease has also been rendered curable in almost half of the patients with the advent of
effective salvage regimens, and, mainly, autologous stem cell transplantation. Furthermore, better
understanding of the biology of HL has permitted the development of targeted therapy. Anti-CD30
targeting with brentuximab vedotin (BV) was the first targeted therapy to be approved for relapsed/
refractory HL, either after autologous stem cell transplantation (auto-SCF) failure or after failure of two
regimens in patients who were not candidates for transplant. Hopefully, the determination of the
optimal role and timing of BV treatment and the development and approval of other targeted com-
pounds will further improve the outcome of advanced stage as well as relapsed/refractory HL.
Semin Hematol 50:4–14. © 2013 Published by Elsevier Inc. Open access under CC BY-NC-ND license.p
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e.Hodgkin’s disease was described by ThomasHodgkin in 1832 in his paper “On some mor-bid appearances of the absorbent glands and
pleen.”1 It is now well recognized that Hodgkin’s
isease is a B-cell lymphoid neoplasm in the vast ma-
ority of cases and the term Hodgkin lymphoma (HL)
as been adopted.
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Sem4Radiotherapy resulted in long-term survival in many
atients with early stages of the disease. However,
dvanced stages remained largely incurable until the
960s. Alkylating agent monotherapy with nitrogen
ustard, sequential treatment with nitrogen mustard and
hlorambucil, etc, resulted in clinical responses in many
atients, albeit without clear evidence of potential cure
ince less than 10% of patients survived for 5 years free of
isease.2 MOPP (mechlorethamine, vincristine, procarba-
zine, prednisone) combination chemotherapy was the
first treatment approach associated with high response
rates and cure of a significant fraction of patients with
advanced disease. Between 1964 and 1976, 188 patients
were treated with MOPP, achieving a complete response
rate of 84% and a 5-year relapse-free survival of 65%–70%
for complete responders.2–4
Since then, the introduction of anthracyclines and
the ABVD (Adriamycin, bleomycin, vinblastine, dacar-
inars in Hematology, Vol 50, No 1, January 2013, pp 4–14
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Progress in advanced and relapsed/refractory Hodgkin lymphoma 5bazine) regimen, further first-line treatment intensifica-
tion with the BEACOPP (bleomycin, etoposide, Adria-
mycin, cyclophosphamide, vincristine, procarbazine,
prednisone) regimen, development of effective salvage
regimens, and high-dose therapy with autologous
stem cell transplantation (auto-SCT), effective risk
stratification, incorporation of functional imaging in
guiding therapy and early prognostic assessment,
and, finally, the development of “targeted”, biologic
therapies, have revolutionized the treatment of HL.
Thus, most patients with HL, including those with
advanced disease as well as a fraction of patients
with relapsed/refractory HL, are now curable. How-
ever, success has come at the expense of increased
acute and long-term toxicity, so that the best balance
between efficacy and toxicity needs to be achieved.
A brief description of the progress made in the field
of advanced stage and relapsed/refractory HL will be
attempted in this review.
ACHIEVEMENTS IN THE
TREATMENT OF ADVANCED DISEASE
The Evolution of
Chemotherapy for Advanced HL
Advanced-stage HL, defined as stage Ann Arbor stage
III and IV (since the classification of stage IIB is con-
troversial), was almost always incurable until the intro-
duction of the MOPP by De Vita and coworkers.3,4 In
he early 1970s, Bonadonna and coworkers developed
he ABVD regimen,5,6 which became the standard of
are until the start of the 21st century and even now.
BVD proved to be superior to MOPP6 and this was
firmly established in a well-known Cancer and Leuke-
mia Group B (CALGB) trial,7 at least in terms of failure-
free survival (FFS).
Based on the long-term results of the above
CALGB trial, the 20-year FFS after ABVD without
radiotherapy in stage III/IV HL is just above 40%
(v 61% at 5 years), while the 20-year overall survival
is 50%–55%. The corresponding figures for MOPP
without radiotherapy are approximately 30% (v 50%
at 5 years) and 40%, respectively.8 However, when
nterpreting these figures, one should keep in mind
he exact definition of FFS: deaths of any cause are
onsidered as events in this analysis, even if relapse
as not occurred.7 Obviously FFS and tumor control
ates are not synonymous; instead they may differ
ubstantially, especially after long follow-up times. In
act, 15-year tumor control rate after ABVD plus
adiotherapy in selected patients is in the order of
0%–65%.9 However, even this figure is not satisfac-
tory, since 35%–40% of the patients will ultimately
require salvage therapy and almost half of them will
succumb to the disease.Several efforts to overcome drug resistance by alter-
nating cycles of MOPP and ABVD,7,8,10–12 creating hy-
brid regimens (MOPP/ABV and similar),10–14 or includ-
ing even more drugs,15–17 were not successful despite
very promising initial results. Indeed, these regimens
were not superior to ABVD or equivalent regimens in
randomized trials.7,8,10–17
Stanford V, a multidrug regimen with reduced go-
nadal toxicity and leukemogenicity, which incorpo-
rated radiation as a major component of treatment, was
developed at Stanford in the late 1980s. Although initial
results were impressive,18 recent randomized trials
failed to show any superiority over ABVD, even if the
whole program including radiotherapy was strictly ap-
plied.15,19,20
During the 1990s, the German Hodgkin Study Group
(GHSG) revolutionized the treatment of advanced HL
with the development of BEACOPP-escalated.21 The
design of this dose- and time-intensified seven-drug
regimen was based on animal studies, retrospective
data, and mathematical models, suggesting that more
rapid chemotherapy administration could improve
5-year FFS by 3% and moderate dose escalation by an
additional 10%.22,23 The HD9 trial, published in 2003,
as the first one to show the superiority of a new
egimen over an ABVD-equivalent, the alternating
OPP/ABVD (cyclophosphamide, vincristine, procar-
azine, prednisone/ABVD) regimen, which was ex-
ended not only to FFS but to overall survival as well.23
HD9 was applicable to patients up to 65 years old with
stage IIB X/E, III, or IV HL. Its mature results revealed
an absolute 18% superiority of BEACOPP-escalated over
COPP/ABVD at 10 years in terms of FFS, which was also
translated to an 11% absolute difference in overall sur-
vival.24 However, acute and long-term toxicity of
EACOPP-escalated was not negligible: grade 3/4
ematologic toxicity was much more frequent, 1.7%
f the patients died of complications of chemother-
py, while a further 3% developed secondary myelo-
ysplastic syndrome (sMDS) and acute non-lympho-
lastic leukemia (ANLL), an almost uniformly fatal
omplication (Table 1; 10-year cumulative incidence,
.2%). Among 14 cases of sMDS/ANLL, nine (64%)
ere diagnosed within the initial 5 years, four (29%)
etween 5 and 7 years, and one (7%) beyond 7 years
rom randomization.24
In an effort to reduce toxicity while maintaining
efficacy, the HD12 trial of the GHSG compared eight
cycles of BEACOPP-escalated with four cycles of this
regimen plus four cycles of BEACOPP-baseline. Efficacy
was similar in the two arms, but the expectations of
reduced toxicity were not fulfilled (Table 1).25 Al-
though acute hematologic toxicity was lower in the
second part of the de-escalated regimen and sMDS/
ANLL appeared to be less frequent compared to HD9,
overall, toxic death, and sMDS/ANLL rates were similar
between the two chemotherapy arms (Table 1). In the
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6 T.P. Vassilakopoulos and M.K. Angelopoulou44 arm, 78% (21/27) of toxic deaths occurred during
the initial four cycles of BEACOPP-escalated, but this
was also the case for 58% (11/19) of the toxic deaths in
the BEACOPP-escalated x 8 arm. Furthermore, HD12
revealed an unacceptably high rate of toxic deaths in
patients 61–65 years old: 17% of these patients died of
treatment toxicity versus 2% of patients 60 years old.
Treatment-related mortality gradually increased by de-
cade in the latter group, being 1% in patients 40
years old and higher in the two older age groups.25
However, it is of interest that, although treatment-
related mortality is expected to be relatively high in
patients aged 50–59 years old, this age group had a
statistically significant survival benefit with BEACOPP-
escalated (v COPP/ABVD) in the HD9 trial, despite the
low number of patients.24
Based on these results, another type of de-escala-
ion was attempted in the HD15 trial of the GHSG,
hich was restricted to patients up to 60 years old.
n this trial, eight cycles of BEACOPP-escalated were
ompared with six cycles of the same regimen or
ight cycles of BEACOPP-14 (BEACOPP-baseline
iven every 14 days).26 The six-cycle arm was not
nferior; instead it was superior to the eight-cycle
rm in terms of both FFS and overall survival. Fur-
hermore, toxicity was minimized: only 0.8% of the
atients died of acute treatment toxicity (a figure
omparable to that observed with ABVD) and the in-
idence of sMDS/ANLL was reduced to 0.3%.26 The
impressive reduction of sMDS/ANLL may be partly re-
lated to threshold doses of cyclophosphamide and pro-
carbazine, although it should be interpreted with cau-
tion, because of the low number of events and the
relatively short median follow-up of only 4 years at the
Table 1. Comparative Frequency of Toxic Dea
Versions of BEACOPP-Escalated and ABVD
Treatment Trial
No. of
Patients R
BEACOPP-esc  8, HD9 466
BEACOPP-esc  8, HD12 787
BEACOPP-esc  8, HD15 705
BEACOPP-esc/base  (44), HD12 787
BEACOPP-esc/base  (44), Italian 156
BEACOPP-esc  6, HD15 711
BEACOPP-esc/base  (42),
HD2000 GISL
98
BEACOPP-14  8, HD15 710
BEACOPP-base  8, HD9 469
COPP/ABVD  8, HD9 261
ABVD  6–8, Italian 166
ABVD  6, HD2000 GISL 99time of publication.The conclusion drawn from these three trial gener-
ations is that six cycles of BEACOPP-escalated is the
current gold standard for advanced HL according to the
GHSG. However, it was not directly compared with
ABVD in these trials.
Two Italian trials compared BEACOPP-based ap-
proaches (four escalated plus two to four cycles of
BEACOPP-baseline) with ABVD.16,27 Both demonstrated
uperiority in terms of FFS but no difference in overall
urvival, although their power to detect overall survival
ifferences may be limited. A recent meta-analysis spe-
ifically suggests that six cycles of BEACOPP-escalated
ay improve overall survival over ABVD.28 In this con-
text, the results of the European Organization for Re-
search and Treatment of Cancer (EORTC) 20012 trial
are awaited with interest. In this trial, patients with
stage III/IV HL and an International Prognostic Score
(IPS) 3 were randomized to either eight cycles of
ABVD or four cycles of BEACOPP-escalated followed by
four cycles of BEACOPP-baseline.29
Overall, it is clear that BEACOPP-escalated is better
than ABVD or equivalents in terms of efficacy in pa-
tients up to 60 years old, although acute treatment-
related mortality may be relatively high in the upper
limit of this age range. Acute and long-term toxicity is
improved by the use of six versus eight cycles, but
issues of infertility, especially in females, may still per-
sist. However, it is also clear that approximately
60%–65% of patients with advanced HL do not need
BEACOPP-escalated, because they will be cured with
ABVD.7–17,19,20,23 Thus, it is of major importance to iden-
tify those patients who will not be cured with ABVD in
order to limit the use of BEACOPP-escalated for the
d MDS/ANLL in Randomized Trials Including
yr)
Median
Follow-up (mo)
Toxic
Deaths (%)
MDS/
ANLL (%)
107 1.7 3.0
78 2.4 1.5
48 2.1 2.7
78 3.4 1.3
61 3.2 1.2
48 0.8 0.3
41 2.0 0
48 0.8 1.1
111 1.5 1.5
122 1.9 0.4
61 0.6 0.6
41 0 0ths an
Age
ange (
16–65
16–65
16–60
16–65
17–60
16–60
16
16–60
16–65
16–65
17–60
16population who may benefit most.
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Progress in advanced and relapsed/refractory Hodgkin lymphoma 7How to Define High-Risk
Patients With Advanced HL
The IPS is the established risk stratification system
for advanced HL.30 However, IPS cannot define a size-
ble subgroup of patients with sufficiently poor prog-
osis, since only 7% of the patients fell into the high-
isk group in the original study and their FFS at 5 years
as 42%.30 Treatment strategies and supportive care
have changed compared to the time of IPS develop-
ment. Thus, more recent data demonstrate that, although
IPS is clearly predictive of outcome, its performance may
not be as good as originally described.13,31–33 Prognosti-
cation may be further improved by the incorporation of
additional conventional prognostic factors,9,34 the iden-
tification of biological prognostic factors,35–46 and the
eliable early response assessment, which might permit
successful early treatment modification.47,48
Although recent progress in understanding the biol-
ogy of HL has resulted in the identification of biological
prognostic factors that work independently of the con-
ventional ones, biological parameters have not been
adopted in everyday practice.35–46,49–51 Major reasons
for this include issues of reproducibility and lack of
prospective validation for the time being. On the other
hand, early response assessment was recently shown to
be a very strong prognostic tool due to the advent of
interim positron emission tomography/computed to-
mography scan (iPET/CT), which can be performed
just before the third cycle of ABVD.
Early Response Assessment and Potential
Treatment Modification in Advanced HL
Interim PET may be the strongest prognostic factor
ever reported for advanced HL, overshadowing the
impact of IPS.48 According to the Deauville criteria, a
ositive iPET/CT is defined as persistence of increased
8-fluoro-deoxyglucose (18-FDG) uptake in disease
ites, exceeding the uptake of the liver, after two cycles
f chemotherapy.52 Based on these criteria, the Inter-
national Validation Study (IVS) demonstrated that pa-
tients with early unfavorable or advanced HL who be-
come iPET-negative enjoy a 5-year FFS of approximately
95% versus only 28% for those who remain iPET-posi-
tive.53 The frequency of iPET positivity in this patient
group is approximately 20%.53,54
In a recent phase II trial, 165 patients with early
unfavorable or advanced HL received two cycles of
ABVD and underwent iPET, which was negative in 137
(83%) and positive in 28 (17%) according to the Deau-
ville criteria.54 Conventional prognostic factors were
not associated with iPET result. Patients with a negative
iPET received four additional ABVD cycles plus radio-
therapy to bulk and/or residuals and achieved a 2-year
FFS of 92%. Among 28 patients with positive iPET, 23
were switched to intensified chemotherapy with four
cycles of BEACOPP-escalated and four BEACOPP-base-line, and five continued on ABVD based on medical
decision. Radiotherapy strategies were the same as in
the iPET-negative cohort. The 23 patients who were
switched to BEACOPP achieved a 2-year FFS of 65%.
This figure is in sharp contrast to the 5-year FFS of 28%,
which was expected for this patient population on the
basis of the IVS results.53
Based on these data, patients with advanced HL who
remain PET/CT-positive after two cycles of ABVD may
be a very realistic target group for early treatment
intensification, in order to avoid the exposure of the
majority of the patients to BEACOPP-escalated. How-
ever, only the results of current randomized trials will
definitely show whether this strategy actually improves
FFS and, more importantly, overall survival in this
group of patients with unfavorable prognosis.53
Defining the Use of
Radiotherapy in Advanced HL
The role of consolidative radiotherapy in patients
with advanced HL responding to chemotherapy is not
well established. Complete responders to standard an-
thracycline-based chemotherapy do not benefit from
radiotherapy,55 but partial remissions by conventional
restaging may convert to complete remissions. Al-
though radiotherapy is probably an integral part of
strategies involving less aggressive chemotherapy, in-
tensified regimens may obviate the need for consolida-
tive radiotherapy. PET-based evaluation of residual
masses may further reduce the need for radiotherapy.
Indeed, in three successive generations of GHSG trials
for advanced HL (HD9, HD12, and HD15), the use of
radiotherapy was reduced from 64% with COPP/ABVD
and 71% with BEACOP-escalated x 8 in HD9, to 11%
after BEACOPP and PET-guided decisions in HD15,
without compromising efficacy. While the use of radio-
therapy could be restricted to patients with 2.5 cm
PET-positive residuals after BEACOPP irrespective of
initial bulk, its exact role in ABVD-treated patients in
the era of PET is not yet well defined. Even those
advanced-stage patients who become PET-negative af-
ter ABVD may have a non-negligible risk of relapse,56
but it is not known whether it could be reduced by
consolidative radiotherapy.
ACHIEVEMENTS IN THE TREATMENT
OF RELAPSED/REFRACTORY DISEASE
A significant proportion of patients with relapsed
and refractory HL has been rendered curable by the
development of effective salvage chemotherapy regi-
mens and the introduction of high-dose therapy/auto-
SCT. Progress in understanding the biology of the dis-
ease was also translated to the development and
approval of the first effective targeted therapy for re-
lapsed/refractory HL: anti-CD30 targeting with bren-
d
p
a
t
i
e
a
m
c
t
s
w
a
e
m
c
v
M
m
C
h
t
8 T.P. Vassilakopoulos and M.K. Angelopouloutuximab vedotin (BV), a drug-conjugated monoclonal
antibody, produced impressive response rates in pa-
tients with very unfavorable outlook.
Conventional Chemotherapy
and High-Dose Therapy With auto-SCT
During the 1970s and 1980s it became evident that
conventional chemotherapy, which is currently used as
first-line therapy of HL, can cure the majority of pa-
tients who were relapsing after radiotherapy alone for
early-stage disease.7,57 Furthermore, MOPP could in-
uce long-term complete remissions in a proportion of
atients who failed ABVD (mainly primary refractory
nd early relapses) and vice versa.7,58 Radiotherapy
alone may cure up to 30% of patients with localized
relapses after chemotherapy.59 Since then, many other
conventional regimens were tested for the treatment of
relapsed/refractory disease, including those based on
platinum, gemcitabine, or both.60–63 However, conven-
ional chemotherapy can produce long-term remissions
n only 30%–40% of patients with relapsed dis-
ase57,64,65 and even fewer of those with refractory
disease.66
High-dose therapy/auto-SCT was introduced in the
treatment of relapsed/refractory HL in the 1980s. Two
randomized trials have shown that conventional sal-
vage therapy followed by high-dose therapy/auto-SCT
is superior to further conventional chemotherapy alone
in terms of freedom from second treatment failure
(FF2TF)67,68in patients with chemosensitive HL. Al-
though overall survival benefits have not been shown,
this may be due to the use of high-dose therapy/auto-
SCT later on in the arms of conventional salvage ther-
apy. Thus, high-dose therapy/auto-SCT may cure 50%–
60% of patients with relapsed HL,68,69 but this figure
ranges between 10%–15% and 75%–80% according to
the number of adverse prognostic factors (0–3).69 Cure
rates are slightly higher for the majority of patients,
who do actually proceed to high-dose therapy/auto-
SCT, but approximately 15%–30% fail to do so because
of inadequate response or progressive disease, unac-
ceptable toxicity, or failure of stem cell collection. The
situation is even less optimistic in the setting of primary
chemorefractory disease: the 5-year FF2TF is 15%–20%
and overall survival does not exceed 30%. The corre-
sponding figures for the subset of patients who actually
receive high-dose therapy/auto-SCT are approximately
30% and 45%, respectively, but, unfortunately, more
than half and up to two thirds of patients with primary
chemorefractory HL fail to undergo high-dose therapy/
auto-SCT.70,71
High-dose therapy/auto-SCT represents a major ad-
vance and has become the treatment of choice for
relapsed/refractory patients with HL after failure of
primary chemotherapy with or without radiotherapy in
younger patients (generally up to 65 years old). How- Sever, there are still three patient groups in whom novel
approaches are needed: (1) patients who cannot un-
dergo high-dose therapy/auto-SCT due to persistently
chemorefractory disease and who have an extremely
poor prognosis; (2) patients who do not achieve com-
plete remission or relapse after high-dose therapy/auto-
SCT, who have a 5-year overall survival probability of
about 30% and are mostly incurable72; in particular,
those who progress within 1 year from auto-SCT have
a median survival of just over 1 year73; and (3) patients
who do not tolerate high-dose therapy/auto-SCT due to
comorbidities or, more frequently, advanced age. No-
tably, if elderly patients (65–70 years old) develop
relapsed/refractory disease, their 5-year survival after
failure is very low, probably due to poor tolerance of
salvage therapy.74,75 A second auto-SCT76,77) or, prefer-
bly, an allogeneic transplant, may be curative for a
inority of patients falling in the second of the above
ategories, but all other patients clearly need novel
reatment approaches.
Brentuximab Vedotin
The development of BV is the major advance of
recent years in the field of HL. CD30, a member of the
tumor necrosis factor receptor (TNFR) superfamily, is
invariably expressed on the surface of Hodgkin and
Reed-Sternberg (HRS) cells of classical HL. Since it is
expressed by only a few types of normal cells, it is
suitable for monoclonal antibody targeting. Initial stud-
ies of CD30 targeting with the SGN-30 monoclonal
antibody were not successful.78,79 BV (SGN-35) was
ubsequently developed as an antibody-drug conjugate
ith three components: (1) the chimeric anti-CD30
ntibody cAC10, (2) an average of 4 (range, 2–8) mol-
cules of the microtubule-disrupting cytotoxic agent
onomethyl auristatin E (MMAE), and (3) a protease-
leavable dipeptide linker, composed of citrulline and
aline, which covalently attaches MMAE to cAC10.
MAE is a potent antimicrotubule cytostatic agent. The
echanism of action of BV against HRS and other
D30 cells is shown in Figure 1. Briefly, the antibody
binds to surface CD30 of the HRS cells. The complex is
then internalized and trafficked into the lysosomes,
where the linker is degraded resulting in the release of
MMAE. MMAE inhibits tubulin polymerization, thus in-
ducing G2M cell cycle arrest and apoptotic cell death.
Diffusion of a small fraction of free MMAE into the
microenvironment results to further cytotoxicity in
non-neoplastic cells, which are crucial for HRS cell
survival.80,81
In August 2011 the US Food and Drug Administra-
tion granted approval of BV for the treatment of adult
patients with relapsed or refractory CD30 HL who
ave failed auto-SCT or following at least two prior
herapies in patients who are not candidates for auto-
CT.
al.
Progress in advanced and relapsed/refractory Hodgkin lymphoma 9Following promising phase I results, the maximal
tolerated dose for BV was determined at 1.8 mg/kg.82
Subsequently, BV was tested in a phase II trial in 102
patients with relapsed/refractory HL who had already
undergone auto-SCT.83 The drug was intravenously ad-
ministered at a dose of 1.8 mg/kg every 3 weeks for a
total of 16 cycles in the absence of prohibitive toxicity
or disease progression. The patients had a median age
of 31 years (range, 15–77) and performance status 0–1
but otherwise had a very unfavorable profile: they had
received a median of 3.5 previous regimens (range,
1–13), 66% had been irradiated, 71% had experienced
primary refractory disease, only 46% had responded to
the most recent systemic therapy, 56% had received
systemic therapy after auto-SCT, while the median time
from auto-SCT to the first post–auto-SCT progression/
relapse was 6.7 months (1 year in 71%). Patients
received a median of nine cycles (range, 1–16) at a high
relative dose-intensity of 96%. Based on central review,
the overall response rate was 75%, including 34% com-
plete responses, but at least some tumor regression was
observed in 94% of the patients. The median progres-
sion-free survival (PFS) was 5.6 months, while among
Figure 1. Mechanism of action of SGN-35. The antibody–d
cells. The complex is then internalized through endocytosis
is formed within the cytoplasm, where it is uncoated and cl
fused with a lysosome and MMAE is released after cleavag
MMAE inhibits tubulin polymerization, thus inducing G2M
MMAE is diffused out of the neoplastic cells, being released i
in non-neoplastic cells, which are crucial for HRS cell survivresponders the median duration of response was 6.7months. However, the median duration of response for
the complete responders was 29 months.83 Interest-
ingly, responses were observed across all subgroups, as
defined by pretreatment patient and disease character-
istics, ie, there was no subgroup of patients who were
unlikely to achieve clinically meaningful antitumor ef-
fects. The 1-year and 2-year overall survival rates were
89% and 65%, respectively.83,84 Median survival has
not yet been reached for complete responders, while it
was 31.6, 20.6, and 10.2 months for patients with
partial responses, stable, or progressive disease, respec-
tively.84
Toxicity with BV in this phase II trial was rather
mild.83 There were no treatment-related deaths. Grade
3 toxicity or higher was observed in 55% of patients,
but grade 4 events were rare. The most common ad-
verse event was peripheral sensory neuropathy, mainly
numbness and tingling of fingers and toes: 42% of
patients developed this side affect, which was of grade
3 severity in 8%, with no grade 4 events. Peripheral
motor neuropathy was observed in 11% of patients
(only 1% grade 3). Treatment was discontinued due to
sensory and motor peripheral neuropathy in six and
njugate binds to CD30 molecules on the surface of the HRS
ed by clathrin. A clathrin-coated vesicle containing SGN-35
recirculates to the cell surface. The uncoated vesicle is then
e dipeptide linker by cathepsin, a lysosomal protein. Free
cle arrest and apoptotic cell death. A small fraction of free
ir microenvironment, where it can exert further cytotoxicityrug-co
mediat
athrine
e of th
cell cy
nto thethree patients, respectively. The median time to onset
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10 T.P. Vassilakopoulos and M.K. Angelopoulouof sensory neuropathy was 12.4 weeks. Sensory neu-
ropathy was improved in 80% of patients and resolved
completely in 50%. Other grade 3/4 adverse events
were mainly confined to laboratory abnormalities: neu-
tropenia was observed in 20% of patients with 6%
grade 4 events but no cases of febrile neutropenia,
thrombocytopenia in 8%, and anemia in 6% of the
patients.
A recent analysis in another very unfavorable popu-
lation of 45 patients from the GHSG further supports
the results of the above phase II trial.85 The patients
ad received a median of four previous regimens
range, 2–12), 18% had an Eastern Cooperative Oncol-
gy Group (ECOG) performance status of 2, 62% had
xperienced primary refractory disease or early re-
apse, 64% were refractory to the most recent therapy,
nd 87% had received auto-SCT or allogeneic SCT (allo-
CT). The overall response rate was 60% including 22%
omplete responses, while 29% of patients had stable
isease. The median PFS was 8 months, but among
esponders it was 13 months. The 1-year overall sur-
ival was 83%. Seventeen patients had very high-risk
isease, defined as primary refractory disease or early
elapse plus refractoriness prior to BV. These patients
as similar response rates (59%), but responses were
ess durable (median PFS, 6 v. 14 months for the re-
aining patients), while overall survival was also
horter (68% v 93% at 1 year).85 When used as first-line
salvage therapy following ABVD or BEACOPP  radio-
therapy, BV is also very active with 100% tumor con-
trol, 87.5% overall response, and 50% complete re-
sponse rates in a small series of 11 (eight evaluable)
patients. Toxicity was mild and BV permitted success-
ful subsequent auto-SCT without compromising stem
cell collection or engraftment after auto-SCT.86
In patients who are not eligible for auto-SCT
(chemorefractoriness, advanced age, comorbidities, in-
adequate stem cell collection, patient’s preferences),
BV may also induce responses, including complete re-
sponses. Notably, a proportion of chemorefractory pa-
tients may become eligible and safely undergo auto-
SCT.87,88
Despite the very high response rates with BV, the
rate of disease control at 2 years with the 16-cycle
regimen is approximately 25%, so that further treat-
ment will be required.89 Reduced-intensity allo-SCT
RIC-alloSCT) may cure some patients after auto-SCT
ailure, but success is highly dependent on pre–RIC-
lloSCT disease control. BV may provide the transient
isease control required to permit RIC-alloSCT. Recent
ata suggest that BV does not adversely affect engraft-
ent, graft-versus-host disease (GVHD), and survival
fter RIC-alloSCT.90 In fact, the results were very prom-
sing in 18 patients, with a 1-year PFS of 92%, 1-year
verall survival of 100%, absence of non-relapse mor-
ality, and incidence of acute and chronic GVHD 28%
nd 56%, respectively.Alternatively, patients who respond to BV can be
e-treated with the same agent. In a phase II trial (NCT
0947856), 14 patients with HL who had previously
esponded to BV and subsequently relapsed or pro-
ressed after having discontinued BV were re-treated
ith 1.8 mg/kg every 3 weeks. The overall response
ate was 57%, including 21% complete responses,
hile an additional 21% of the patients had stable
isease. The median duration of response (including
ight patients with anaplastic large cell lymphoma) was
0.8 months. Re-treatment appeared to be safe.91 Pro-
longed treatment with BV beyond 16 cycles is fea-
sible.92 Whether prolonged treatment may improve
isease control or even survival compared with on-
emand re-treatment or other treatment strategies is
ot known.
In the pivotal phase II trial, patients had not received
llo-SCT.83 The efficacy of BV after allo-SCT was evalu-
ted in 25 HL patients, 11 of whom had received
ransplants from unrelated donors.93 BV was adminis-
tered for a median of 8 cycles (1–16) at doses of 1.2 or
1.8 mg/kg every 3 weeks. In this heavily pretreated
population with a median of 9 (range, 5–19) prior
regimens, disease control, overall response and CR
rates were 92%, 50% and 38% respectively and the
median PFS was 7.8 months. However, the median
time from allo-SCT to BV initiation was 42 months,
indicating that many patients had rather slowly pro-
gressing disease. Furthermore, more than 100 days had
elapsed from allo-SCT in all patients and none of them
had experienced relapse in the presence of active
GVHD; thus very high-risk patients were excluded.
These data support the use of BV in selected patients
after allo-SCT failure. Since CD30 is expressed on acti-
vated T cells, BV might further impair cell-mediated
immunity in allo-transplant recipients. Cytomegalovirus
(CMV) viremia and infection might be of concern, so
that CMV monitoring is advisable in this setting.
Based on the very promising data reported so far, BV
is currently being tested in several studies. For exam-
ple, the AETHERA study (NCT 01100502) compares BV
maintenance versus placebo in patients with high risk
of recurrence after allo-SCT.81 BV is also being tested as
art of the first-line therapy with the ABVD or AVD
egimen.94 Data suggest that bleomycin should be omit-
ed because of excess, potentially lethal, pulmonary
oxicity. Initial results demonstrated that themaximal tol-
rated dose is at least 1.2 mg/kg every 2 weeks and that
nterim PET after two cycles of immunochemotherapy
as negative in 46/48 patients, while end-of-treatment
esults appear very promising.94 Thus, it is planned to
test BV–AVD against ABVD alone in a phase III trial of
advanced HL. Similarly, the GHSG will conduct a phase
II trial to evaluate BV in combination with a modified
version of BEACOPP (bleomycin omitted) in previously
untreated advanced classical HL.
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During the last 50 years there has been great prog-
ress in understanding the biology of Hodgkin’s disease,
which is now called Hodgkin lymphoma, since it has
been definitely shown to be a lymphoid neoplasm and
its B-cell origin has been documented in the vast ma-
jority of cases. Progress in biology has also resulted in
the identification of numerous biological prognostic
factors, which may facilitate the definition of high-risk
groups of patients and provide guidance for individu-
alized therapy. Unfortunately, biological prognostic fac-
tors have not been incorporated in prognostic models
applicable in everyday practice and need prospective
validation.
More importantly, during the last 50 years, ad-
vanced-stage HL has been transformed from a rather
incurable to a highly curable disease. Chemotherapy
has gradually improved in terms of efficacy. MOPP was
replaced by the more efficacious and less toxic ABVD
regimen, but higher cure rates with BEACOPP-esca-
lated have come at the expense of increased toxicity.
Better risk stratification, probably based on early, in-
terim PET evaluation, may in the near future better
identify those patients who really need intensified che-
motherapy. Furthermore, the intensification of chemo-
therapy and the optimal use of PET at the end of
chemotherapy have already minimized the use of radio-
therapy in advanced disease, thus reducing the risk of
long-term complications. Relapsed and refractory dis-
ease has also been rendered curable in many patients
with the advent of effective salvage regimens, and,
mainly, auto-SCT. These advances are reflected in the
improvement of survival rates reported between 1980
and 2004.95
Furthermore, better understanding of the biology of
HL has permitted the development of targeted therapy.
Anti-CD30 targeting with BV was the first targeted
therapy to be approved for relapsed/refractory HL,
either after auto-SCT failure or after failure of two
regimens in patients who are not candidates for trans-
plant. Hopefully, the determination of the optimal role
and timing of BV treatment and the development and
approval of other targeted compounds will further im-
prove the outcome of advanced stage as well as re-
lapsed/refractory HL.
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